[caption id="attachment_73594" align="aligncenter" width="500"] Photo by Christina Victoria Craft on Unsplash[/caption]
Treatment options for hematologic malignancies have evolved considerably over the past decade. Bruton's tyrosine kinase (BTK) inhibitors are an important class of targeted agents that have been introduced into clinical practice for the management of select blood cancers, with multiple clinical studies evaluating their impact on disease outcomes.
These therapies work by targeting a specific enzyme involved in B-cell signaling — a pathway that is dysregulated in several B-cell malignancies — and have received regulatory approval for use in a number of hematologic conditions.
Photo by Christina Victoria Craft on Unsplash[/caption]
Treatment options for hematologic malignancies have evolved considerably over the past decade. Bruton's tyrosine kinase (BTK) inhibitors are an important class of targeted agents that have been introduced into clinical practice for the management of select blood cancers, with multiple clinical studies evaluating their impact on disease outcomes.
These therapies work by targeting a specific enzyme involved in B-cell signaling — a pathway that is dysregulated in several B-cell malignancies — and have received regulatory approval for use in a number of hematologic conditions.